Lancet Infectious Diseases study compare well with phase 3 clinical trials of Covaxin: Bharat Biotech

Credit: IndiaTimes- Published on November 25, 2021
Commenting on the study of the Lancet Infectious Diseases on the effectiveness of Covaxin (BBV152) against symptomatic RT-PCR, the Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obtained during controlled phase 3 clinical trials of Covaxin conducted among...

You are here

๐Ÿ’ก newsR Knowledge: Other News Mentions

Bharat Biotech

Indian multinational biotechnology company and vaccine manufacturer

Related videos from verified sources

Bharat Biotech: Do not use pain killers after vaccination with Covaxin | Oneindia News 03:21
Credit: Oneindia - Published 2 weeks ago 

Covaxin approved for children between the age of 12 to 15 years by DGGI | Oneindia News 01:38
Credit: Oneindia - Published on December 26, 2021 

New Eye Drops May Help People With Age-Related Vision Problems 01:31
Credit: Wibbitz Top Stories - Published on December 14, 2021 

You might like